Skip to main content
Premium Trial:

Request an Annual Quote

Decipher Biosciences, Dendreon Pharmaceuticals Ink Prostate Cancer Research Deal

NEW YORK (GenomeWeb) — Decipher Biosciences — formerly GenomeDx Biosciences — announced today that it has signed an agreement to help Dendreon Pharmaceuticals identify patients who are likely to respond to its prostate cancer therapy Provenge (sipuleucel-T).

Provenge is a US Food and Drug Administration-approved autologous cellular immunotherapy. Under the terms of the deal, the Decipher assay will be used to assess the biological behavior of tumors from patients enrolled in a phase III study of Provenge. It will also evaluate tumor gene expression signatures that may be associated with Provenge response..

The Decipher assay is designed to provide a genomic assessment of tumor aggressiveness for individual patients and is derived from the San Diego-based company's Genomics Resource Information Database of urologic tumor genomic profiles.

Additional terms were not disclosed

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.